Brief: Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data At Sleep 2026, Demonstrating Real-World Impact Of Xywav
16/06/2026 21:09
BRIEF-Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data At Sleep 2026, Demonstrating Real-World Impact Of Xywav June 16 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O:
JAZZ PHARMACEUTICALS DELIVERS EXTENSIVE LATE-BREAKING DATA AT SLEEP 2026, DEMONSTRATING REAL-WORLD IMPACT OF XYWAV® (CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES) ON PATIENT OUTCOMES ACROSS NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA
Source text: ID:nPnbmpYjHa
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032